Literature DB >> 3336235

Anatomic repair of anomalies of ventriculoarterial connection associated with ventricular septal defect. I. Criteria of surgical decision.

R Sakata1, Y Lecompte, A Batisse, L Borromée, Y Durandy.   

Abstract

The feasibility of anatomic repair (defined as the reconstruction of normal ventriculoarterial connection) was investigated in 104 patients who underwent an operation for anomalies of ventriculoarterial connection associated with ventricular septal defect. Three types of anatomic repair were used: intraventricular rerouting, REV (association of intraventricular rerouting with translocation of the pulmonary arterial trunk on the right ventricle), and arterial switch associated with closure of the ventricular septal defect. Intraventricular repair was considered to be the best and simplest method when possible. In the other cases, REV was indicated if pulmonary outflow tract obstruction was present, and arterial switch was performed when the tract was patent. The feasibility of intraventricular repair was related to the distances between the tricuspid valve and the semilunar valves. Preoperative measurement of these distances is an essential criterion to choose the appropriate repair of anomalies of ventriculoarterial connection associated with ventricular septal defect.

Entities:  

Mesh:

Year:  1988        PMID: 3336235

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  2 in total

1.  Echocardiographic Classification and Surgical Approaches to Double-Outlet Right Ventricle for Great Arteries Arising Almost Exclusively from the Right Ventricle.

Authors:  Kun-Jing Pang; Hong Meng; Sheng-Shou Hu; Hao Wang; David Hsi; Zhong-Dong Hua; Xiang-Bin Pan; Shou-Jun Li
Journal:  Tex Heart Inst J       Date:  2017-08-01

Review 2.  Narrative review of assessing the surgical options for double outlet right ventricle.

Authors:  Antonio F Corno; Saravanan Durairaj; Gregory J Skinner
Journal:  Transl Pediatr       Date:  2021-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.